MedTrace Logo

Bioavailability and Bioequivalence of Ezetimibe Tablets in Healthy Subjects

NCT05681247 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 59

Last updated 2023-01-12

No results posted yet for this study

Summary

This study was conducted to assess the bioequivalence of the ezetimibe tablet to Ezetrol ® in healthy Chinese volunteers and estimate the pharmacokinetic profiles of ezetimibe tablet.

Conditions

  • Hyperlipidemias

Interventions

DRUG

ezetimibe tablet

The subjects randomly received single oral administration of ezetimibe tablet 10 mg

DRUG

ezetimibe tablet(Ezetrol ®)

The subjects randomly received single oral administration of ezetimibe tablet (Ezetrol ®) 10 mg.

Sponsors & Collaborators

  • The Affiliated Hospital of Qingdao University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-12-17
Primary Completion
2018-01-29
Completion
2018-03-07

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05681247 on ClinicalTrials.gov